The Recommended Dose of Ertapenem is the Potential Risk of Neurotoxicity for Hemodialysis Patients

Trial Profile

The Recommended Dose of Ertapenem is the Potential Risk of Neurotoxicity for Hemodialysis Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2016

At a glance

  • Drugs Ertapenem (Primary)
  • Indications Bacterial infections; Renal failure
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 03 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top